TY - JOUR
T1 - Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis
AU - Varotti, Giovanni
AU - Gondolesi, Gabriel E.
AU - Roayaie, Sasan
AU - Suriawinata, Arief
AU - Soltys, Kyle
AU - Fishbein, Thomas M.
AU - Schwartz, Myron E.
AU - Miller, Charles
PY - 2003/11
Y1 - 2003/11
N2 - BACKGROUND: Liver transplantation is the best therapeutic option for patients with end-stage liver disease from primary sclerosing cholangitis. Primary sclerosing cholangitis is associated with a markedly increased risk of cholangiocarcinoma, which adversely affects survival. Approximately 20% to 30% of cholangiocarcinomas are localized in the distal bile duct. Pancreatoduodenectomy is the curative therapy for cholangiocarcinomas in this location. STUDY DESIGN: We reviewed our data on a patient with primary sclerosing cholangitis-related end-stage liver disease and a simultaneous distal bile duct tumor, which was treated with a combined right-lobe, living-donor liver transplantation and pancreatoduodenectomy. RESULTS: The patient was discharged 32 days post-transplantation. He is currently alive 1 year after the procedure with no evidence of recurrent cancer. CONCLUSIONS: Combined living-donor liver transplantation and pancreatoduodenectomy is feasible and allows timely and elective surgical control of carefully selected distal bile duct tumors in the setting of end-stage liver disease.
AB - BACKGROUND: Liver transplantation is the best therapeutic option for patients with end-stage liver disease from primary sclerosing cholangitis. Primary sclerosing cholangitis is associated with a markedly increased risk of cholangiocarcinoma, which adversely affects survival. Approximately 20% to 30% of cholangiocarcinomas are localized in the distal bile duct. Pancreatoduodenectomy is the curative therapy for cholangiocarcinomas in this location. STUDY DESIGN: We reviewed our data on a patient with primary sclerosing cholangitis-related end-stage liver disease and a simultaneous distal bile duct tumor, which was treated with a combined right-lobe, living-donor liver transplantation and pancreatoduodenectomy. RESULTS: The patient was discharged 32 days post-transplantation. He is currently alive 1 year after the procedure with no evidence of recurrent cancer. CONCLUSIONS: Combined living-donor liver transplantation and pancreatoduodenectomy is feasible and allows timely and elective surgical control of carefully selected distal bile duct tumors in the setting of end-stage liver disease.
UR - http://www.scopus.com/inward/record.url?scp=0642280345&partnerID=8YFLogxK
U2 - 10.1016/j.jamcollsurg.2003.06.001
DO - 10.1016/j.jamcollsurg.2003.06.001
M3 - Article
C2 - 14585411
AN - SCOPUS:0642280345
SN - 1072-7515
VL - 197
SP - 765
EP - 769
JO - Journal of the American College of Surgeons
JF - Journal of the American College of Surgeons
IS - 5
ER -